News Releases

May 17, 2022
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 ASCO Annual Meeting LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first
» Full Release
May 12, 2022
LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies
UTRECHT, The Netherlands and PHILADELPHIA, May 12, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer,
» Full Release
May 5, 2022
LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced
» Full Release
April 27, 2022
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced
» Full Release
March 24, 2022
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022 LAVA-1207 Phase 1/2a trial in mCRPC on track to report initial data in H2 2022 New pipeline program: LAVA-1266, a CD123-directed Gammabody™   for
» Full Release
March 10, 2022
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
UTRECHT, The Netherlands and PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of
» Full Release
March 7, 2022
LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome Pharmacodynamic markers indicate increasing receptor occupancy with increasing doses of LAVA-051 and activation of Vγ9Vδ2 T cells Preclinical data presented on LAVA’s lead
» Full Release
February 1, 2022
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
LAVA’s Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the Clinic UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.  ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of
» Full Release
January 28, 2022
Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of
» Full Release
January 18, 2022
LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference
The collective data indicate that LAVA’s approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and cytokine release syndrome (CRS), potentially translating in a superior therapeutic index compared to
» Full Release